Evidence map›Paper›PMID 37994013›Full record

ArticleThe American journal of case reports2023

A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.

Qin Zhou, Mengchen Yu, Xin Chang, Shenglan Shang, Min Li, Weitian Xu

Open access · hybridAbstract readCase Reports
In one paragraph

Article in The American journal of case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Qin ZhouDepartment of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).
Mengchen YuDepartment of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).
Xin ChangDepartment of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).ORCID 0000-0002-7623-188X
Shenglan ShangDepartment of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).ORCID 0000-0002-2771-6100
Min LiDepartment of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).
Weitian XuDepartment of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).
Central Hospital of Wuhan · CNGeneral Hospital of Central Theater Command

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND Hyperphosphatemia is a complication of chronic renal failure (CRF) due to reduction in the glomerular filtration rate. Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia, but has adverse effects if patients are not monitored. This report is of a 47-year-old man with hyperphosphatemia due to CRF treated with lanthanum carbonate tablets who presented acutely with partial large bowel obstruction. The incidence of lanthanum carbonate causing intestinal obstruction is rare, and few cases in the literature have described the course of the disease in detail. CASE REPORT A 47-year-old man diagnosed with diabetic nephropathy underwent hemodialysis treatment and was prescribed 0.5 g/day of chewable lanthanum carbonate tablets. After taking lanthanum carbonate for 5 months, the patient experienced symptoms of decreased bowel movements and exhaustion, which progressively worsened. Abdominal computed tomography (CT) revealed multiple hyperdensities in the large bowel, indicating the presence of lanthanum deposition. Lanthanum carbonate was promptly discontinued. After undergoing enema and catharsis treatment, the large bowel obstruction was relieved, and the hyperdensities in the abdominal CT disappeared. The colonoscopy and histologic examination revealed ulcerations and inflammatory changes in the large bowel mucosa. CONCLUSIONS This report highlights the rare association between the use of lanthanum carbonate tablets and intestinal obstruction. Healthcare providers should enhance their vigilance regarding lanthanum carbonate-induced serious gastrointestinal adverse reactions and actively seek to detect lanthanum deposition by abdominal CT or radiography (X-ray). After the occurrence of lanthanum deposition, drug withdrawal and promotion of defecation are primary treatment methods.

Indexed as

HyperphosphatemiaIntestinal ObstructionKidney Failure, ChronicRenal Insufficiency, ChronicHumansLanthanumMaleMiddle AgedRenal DialysisTabletsLanthanumlanthanum carbonateTablets

Identifiers

PMID37994013
PMCPMC11009886
OpenAlexW4387936842

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.